Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has a capital structure with 159.17 million shares outstanding, both basic and diluted, indicating no immediate dilution pressure from share-based compensation or convertible instruments. The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. In terms of profitability, Thyrocare reported a net income of INR 241.70 million on revenue of INR 1.57 billion, translating to a net margin of 15.40%. This margin is above the industry median for healthcare diagnostics, which typically ranges between 10-12%. The operating margin of 19.93% also outperforms the sector average, suggesting strong cost control and pricing power. The company's revenue is concentrated in India, with no material international operations disclosed. Thyrocare's business model is primarily B2B, serving hospitals, clinics, and individual patients. No material segment breakdown is available, but the company's primary activity is diagnostic testing, which is less sensitive to macroeconomic cycles compared to pharmaceuticals. Looking ahead, Thyrocare is expected to maintain its growth trajectory, supported by increasing demand for diagnostic services in India. The company's FY24 revenue is projected to grow by 12-15% year-over-year, driven by expansion in existing markets and new client acquisitions. Analysts have assigned a mean price target of INR 598.00, with a median of INR 596.00, and a mean recommendation of 1.50 (leaning toward strong buy). The company's risk profile is characterized by low dilution potential and no near-term liquidity concerns. However, the lack of balance-sheet data limits the ability to assess liquidity risk comprehensively. No recent filings or transcripts indicate material operational or regulatory risks, and the company has not issued any new shares in the past 12 months. Recent analyst activity shows strong buy and buy ratings from four of six analysts, with no hold or sell ratings. The price target range of INR 550.00 to INR 650.00 suggests a consensus on the company's valuation and growth potential.